Mason Joe's Album: Wall Photos
Human
Microbiome-based Products Market is growing at an annualized rate of over
40%.
Over the years, extensive R&D efforts have
established the basis for a wide range of microbiome-based therapeutic and
diagnostic products, which may cause a paradigm shift in the way healthcare is
delivered in the foreseen future
Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030”
report to its list of offerings.
The concept of
microbiome-based therapeutics has generated significant enthusiasm within the
medical science community, defining a new frontier in the field of medicine.
Despite having captured the interest of several venture capital firms and big
pharma players, no microbiome-based therapeutic has been officially approved by
an authorized medical product regulator. However, the current development
pipeline of microbiome therapeutics has several promising candidates that are
likely to result in commercial success stories soon.
To order this 640+
page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
Key Market Insights
260
therapy candidates are currently in different phases of development
Nearly 25% of
pipeline drugs are in the clinical phase of development, while the rest are in the
preclinical / discovery stage. Interestingly, most of these drugs target
digestive and gastrointestinal disorders (20%); this is followed by product
candidates intended for treatment of oncological disorders (17%) and infectious
diseases (13%).
Over
30 microbiome diagnostic tests are currently available / under development
Around
30% of the abovementioned tests have been commercialized, while the rest are
under development. Of the total tests, notable examples of companies that launched
a microbiome-based diagnostic solution include (in alphabetical order)
ARTPred, Genetic Analysis, Goodgut, Invivo Healthcare, IS-diagnostics, Luxia
Scientific and Varinos.
FMTs
are the only commercially available microbiome therapy
This
therapeutic product is presently indicated for the treatment of recurrent Clostridium
difficile infections (rCDIs). Further, non-industry players (such as
University of Alberta, The Second Hospital of Nanjing Medical University,
University of California and Chinese University of Hong Kong) are making
notable contributions in this arena, having been involved in ~200 clinical
trials till August 2019.
Contract
service providers have become an integral part of the microbiome supply chain
Presently,
certain firms claim to offer a wide array of contract research / manufacturing
services for microbiome therapeutics. Examples of such players include Adare
Pharmaceuticals, Biose, Cobra Biologics, CoreBiome, List Biological
Laboratories, NIZO, ProDigest, Quay Pharma and Wacker Chemie.
North
America and Europe are anticipated to capture over 85% of the market share by
2030
As late
stage products are commercialized, the microbiome therapeutics market is likely
to grow at an annualized growth rate of over 30%, during the next decade. In
addition to North America and Europe, the market in China / broader Asia
Pacific region is also anticipated to grow at a relatively faster rate.
To request a sample
copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
The USD 4 billion (by 2030) financial opportunity
within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has
been analyzed across the following segments:
§ Type
of Therapy (Tx)
§ Prescription
Drug
§ Prebiotics
§ Probiotics
§ Type
of Molecule (Tx)
§ Small
Molecules
§ Biologics
§ Target
Indication (Tx+Dx)
§ Acne
Vulgaris
§ Atopic
Dermatitis
§ Clostridium
difficile Infection
§ Colorectal
Cancer
§ Crohn’s
Disease
§ Diabetes
§ Irritable
Bowel Syndrome
§ Lactose
Intolerance
§ Lung
Cancer
§ Nonalcoholic
steatohepatitis (NASH)
§ Obesity
§ Ulcerative
colitis
§ Therapeutic
Area (Tx+Dx)
§ Autoimmune
Disorders
§ Dental
Disorders
§ Digestive
and Gastrointestinal Disorders
§ Dermatological
Disorders
§ Infectious
Disease
§ Metabolic
Disorders
§ Oncology
§ Others
§ Key
Geographical Regions (Tx+Dx)
§ North
America
§ Europe
§ Asia-Pacific
and Rest of the World
The report features
inputs from eminent industry stakeholders, according to whom innovation in
microbiome-related research is mostly being driven by start-ups / small-sized
companies. The report includes detailed transcripts of discussions held with
the following experts:
§
Veronika Oudova (Co-founder and Chief Executive Officer,
S-Biomedic)
§
Colleen Cutcliffe (Co-founder and Chief Executive Officer,
Whole Biome)
§
Lee Jones (President and Chief Executive Officer, Rebiotix)
§
Mark Heiman (Chief Scientific Officer and Vice President,
Research, MicroBiome Therapeutics)
§
Assaf Oron (Chief Business Officer, BiomX)
§
Pierre-Alain Bandinelli (Chief Business Officer, Da
Volterra)
§
Nikole E Kimes (Co-founder and Vice President, Siolta
Therapeutics)
§
James Burges (Executive Director, OpenBiome)
§
JP Benya (Vice President, Business Development, Assembly
Biosciences)
§
Debbie Pinkston (Vice President, Sales and Business
Development, List Biological Laboratories)
§
Gregory J Kuehn (Vice President, Business Development and
Marketing, Metabiomics)
§
Alexander Segal (Vice President, Business Development,
Universal Stabilization Technologies)
§
Alexander Lin (Associate General Manager, Chung Mei
Pharmaceutical)
§
Aaron Wright (Senior Scientist, Pacific Northwest National
Laboratories)
The research covers
detailed profiles, featuring a brief company overview, its financial
information (if available), product
portfolio details (such as status of development of pipeline candidates,
clinical trial information and analysis of key trial end-points), recent
developments and an informed future outlook.
§ 4D
Pharma
§ Armata
Pharmaceuticals
§ Evelo
Biosciences
§ Rebiotix
(Acquired by Ferring Pharmaceuticals)
§ Seres
Therapeutics
§ Vedanta
Biosciences
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Antibody Drug Conjugates Market (5th Edition), 2019-2030
2.
Gene Therapy Market (3rd Edition), 2019 - 2030
3.
Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th
Edition), 2019 – 2030
4.
Synthetic Lethality-based Drugs and Targets Market,
2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter
- https://twitter.com/RootsAnalysis
Microbiome-based Products Market is growing at an annualized rate of over
40%.
Over the years, extensive R&D efforts have
established the basis for a wide range of microbiome-based therapeutic and
diagnostic products, which may cause a paradigm shift in the way healthcare is
delivered in the foreseen future
Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030”
report to its list of offerings.
The concept of
microbiome-based therapeutics has generated significant enthusiasm within the
medical science community, defining a new frontier in the field of medicine.
Despite having captured the interest of several venture capital firms and big
pharma players, no microbiome-based therapeutic has been officially approved by
an authorized medical product regulator. However, the current development
pipeline of microbiome therapeutics has several promising candidates that are
likely to result in commercial success stories soon.
To order this 640+
page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
Key Market Insights
260
therapy candidates are currently in different phases of development
Nearly 25% of
pipeline drugs are in the clinical phase of development, while the rest are in the
preclinical / discovery stage. Interestingly, most of these drugs target
digestive and gastrointestinal disorders (20%); this is followed by product
candidates intended for treatment of oncological disorders (17%) and infectious
diseases (13%).
Over
30 microbiome diagnostic tests are currently available / under development
Around
30% of the abovementioned tests have been commercialized, while the rest are
under development. Of the total tests, notable examples of companies that launched
a microbiome-based diagnostic solution include (in alphabetical order)
ARTPred, Genetic Analysis, Goodgut, Invivo Healthcare, IS-diagnostics, Luxia
Scientific and Varinos.
FMTs
are the only commercially available microbiome therapy
This
therapeutic product is presently indicated for the treatment of recurrent Clostridium
difficile infections (rCDIs). Further, non-industry players (such as
University of Alberta, The Second Hospital of Nanjing Medical University,
University of California and Chinese University of Hong Kong) are making
notable contributions in this arena, having been involved in ~200 clinical
trials till August 2019.
Contract
service providers have become an integral part of the microbiome supply chain
Presently,
certain firms claim to offer a wide array of contract research / manufacturing
services for microbiome therapeutics. Examples of such players include Adare
Pharmaceuticals, Biose, Cobra Biologics, CoreBiome, List Biological
Laboratories, NIZO, ProDigest, Quay Pharma and Wacker Chemie.
North
America and Europe are anticipated to capture over 85% of the market share by
2030
As late
stage products are commercialized, the microbiome therapeutics market is likely
to grow at an annualized growth rate of over 30%, during the next decade. In
addition to North America and Europe, the market in China / broader Asia
Pacific region is also anticipated to grow at a relatively faster rate.
To request a sample
copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
The USD 4 billion (by 2030) financial opportunity
within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has
been analyzed across the following segments:
§ Type
of Therapy (Tx)
§ Prescription
Drug
§ Prebiotics
§ Probiotics
§ Type
of Molecule (Tx)
§ Small
Molecules
§ Biologics
§ Target
Indication (Tx+Dx)
§ Acne
Vulgaris
§ Atopic
Dermatitis
§ Clostridium
difficile Infection
§ Colorectal
Cancer
§ Crohn’s
Disease
§ Diabetes
§ Irritable
Bowel Syndrome
§ Lactose
Intolerance
§ Lung
Cancer
§ Nonalcoholic
steatohepatitis (NASH)
§ Obesity
§ Ulcerative
colitis
§ Therapeutic
Area (Tx+Dx)
§ Autoimmune
Disorders
§ Dental
Disorders
§ Digestive
and Gastrointestinal Disorders
§ Dermatological
Disorders
§ Infectious
Disease
§ Metabolic
Disorders
§ Oncology
§ Others
§ Key
Geographical Regions (Tx+Dx)
§ North
America
§ Europe
§ Asia-Pacific
and Rest of the World
The report features
inputs from eminent industry stakeholders, according to whom innovation in
microbiome-related research is mostly being driven by start-ups / small-sized
companies. The report includes detailed transcripts of discussions held with
the following experts:
§
Veronika Oudova (Co-founder and Chief Executive Officer,
S-Biomedic)
§
Colleen Cutcliffe (Co-founder and Chief Executive Officer,
Whole Biome)
§
Lee Jones (President and Chief Executive Officer, Rebiotix)
§
Mark Heiman (Chief Scientific Officer and Vice President,
Research, MicroBiome Therapeutics)
§
Assaf Oron (Chief Business Officer, BiomX)
§
Pierre-Alain Bandinelli (Chief Business Officer, Da
Volterra)
§
Nikole E Kimes (Co-founder and Vice President, Siolta
Therapeutics)
§
James Burges (Executive Director, OpenBiome)
§
JP Benya (Vice President, Business Development, Assembly
Biosciences)
§
Debbie Pinkston (Vice President, Sales and Business
Development, List Biological Laboratories)
§
Gregory J Kuehn (Vice President, Business Development and
Marketing, Metabiomics)
§
Alexander Segal (Vice President, Business Development,
Universal Stabilization Technologies)
§
Alexander Lin (Associate General Manager, Chung Mei
Pharmaceutical)
§
Aaron Wright (Senior Scientist, Pacific Northwest National
Laboratories)
The research covers
detailed profiles, featuring a brief company overview, its financial
information (if available), product
portfolio details (such as status of development of pipeline candidates,
clinical trial information and analysis of key trial end-points), recent
developments and an informed future outlook.
§ 4D
Pharma
§ Armata
Pharmaceuticals
§ Evelo
Biosciences
§ Rebiotix
(Acquired by Ferring Pharmaceuticals)
§ Seres
Therapeutics
§ Vedanta
Biosciences
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Antibody Drug Conjugates Market (5th Edition), 2019-2030
2.
Gene Therapy Market (3rd Edition), 2019 - 2030
3.
Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th
Edition), 2019 – 2030
4.
Synthetic Lethality-based Drugs and Targets Market,
2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
- https://twitter.com/RootsAnalysis